Cargando…

Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study

BACKGROUND: Talazoparib, a poly(ADP-ribose) polymerase enzyme inhibitor, is approved for the treatment of patients with germline BRCA1/2 (gBRCA1/2)-mutated HER2-negative advanced breast cancer. This two-part study, a recently published dose-escalation part followed by the dose-expansion part reporte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotani, Haruru, Masuda, Norikazu, Yamashita, Toshinari, Naito, Yoichi, Taira, Tetsuhiko, Inoue, Kenichi, Takahashi, Masato, Yonemori, Kan, Toyoizumi, Shigeyuki, Mori, Yuko, Nagasawa, Takashi, Hori, Natsuki, Iwata, Hiroji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587945/ https://www.ncbi.nlm.nih.gov/pubmed/35907135 http://dx.doi.org/10.1007/s12282-022-01390-w

Ejemplares similares

Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
por: Naito, Yoichi, et al.
Publicado: (2021)

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
por: Blum, Joanne L., et al.
Publicado: (2022)

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity
por: Litton, J. K., et al.
Publicado: (2017)

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
por: Hurvitz, Sara A., et al.
Publicado: (2019)

Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer
por: Savill, Kristin M Zimmerman, et al.
Publicado: (2023)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer
por: Belz, Jodi E., et al.
Publicado: (2017)

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
por: Litton, Jennifer K, et al.
Publicado: (2023)

Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
por: Im, Seock-Ah, et al.
Publicado: (2020)

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
por: Liu, Xuan, et al.
Publicado: (2022)

Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy
por: Polyanskaya, Elizaveta, et al.
Publicado: (2023)

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial
por: Schram, Alison M., et al.
Publicado: (2022)

Timely Genetic Testing and Therapy Management in Patients With gBRCA-Mutated Metastatic Breast Cancer Receiving Talazoparib
por: Martinez, Ashley, et al.
Publicado: (2022)

A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
por: Gruber, Joshua J., et al.
Publicado: (2022)

Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
por: Zhang, Di, et al.
Publicado: (2021)

Palbociclib as an early-line treatment for Japanese patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: a review of clinical trial and real-world data
por: Masuda, Norikazu, et al.
Publicado: (2021)

Evidence to date: talazoparib in the treatment of breast cancer
por: Exman, Pedro, et al.
Publicado: (2019)

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature
por: Albarrán, Víctor, et al.
Publicado: (2023)

Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study
por: Turner, Nicholas C., et al.
Publicado: (2023)

Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy
por: Takatsuka, Daiki, et al.
Publicado: (2023)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

Current Status of Advance Care Planning and End‐of‐life Communication for Patients with Advanced and Metastatic Breast Cancer
por: Sagara, Yasuaki, et al.
Publicado: (2021)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

BRCA1 and BRCA2 germline mutation analysis in the Indonesian population
por: Purnomosari, Dewajani, et al.
Publicado: (2007)

Analysis of Oncogenes and Tumor Suppressor Genes in Human Breast Cancer
por: Yamashita, Hiroko, et al.
Publicado: (1993)

Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2)
por: Tamura, Kenji, et al.
Publicado: (2023)

Circulating tumor cells detection in tumor draining vein of breast cancer patients
por: Hattori, Masaya, et al.
Publicado: (2019)

Time to Chemotherapy for Patients With Estrogen Receptor-Positive Breast Cancer and Cyclin-Dependent Kinase 4 and 6 Inhibitor Use
por: Endo, Yuka, et al.
Publicado: (2022)

Single-dose trastuzumab monotherapy achieved pathological complete response (pCR) in a patient with HER2-positive breast cancer: a case report
por: Isogai, Ayaka, et al.
Publicado: (2023)

A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice
por: Zhang, Di, et al.
Publicado: (2019)

Evaluation of models to predict BRCA germline mutations
por: Kang, H H, et al.
Publicado: (2006)

The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population
por: Stegel, Vida, et al.
Publicado: (2011)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
por: Boussios, Stergios, et al.
Publicado: (2020)

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
por: Li, Jiaguo, et al.
Publicado: (2020)

A Phase I trial of talazoparib in patients with advanced hematologic malignancies
por: Gopal, Ajay K, et al.
Publicado: (2021)

Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
por: Klein, Florian G., et al.
Publicado: (2021)

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
por: Zhou, Dong, et al.
Publicado: (2021)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

A case of radiation-associated angiosarcoma after breast cancer
por: Horisawa, Nanae, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lh9kg4ihk80h227rhvnit4ins2